Rosen Law Firm Urges Intellia Therapeutics Investors to Take Action Before Deadline

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a well-known global investor rights law firm, is reminding all shareholders of Intellia Therapeutics, Inc. (NASDAQ: NTLA) who purchased securities between July 30, 2024, and January 8, 2025, of the critical April 14, 2025 lead plaintiff deadline.

SO WHAT: If you bought shares of Intellia during the mentioned Class Period, you might be eligible to receive compensation without incurring any out-of-pocket expenses, as the law firm operates on a contingency fee basis.

WHAT TO DO NEXT: To get involved in the Intellia class action, please visit this link or contact Phillip Kim, Esq., toll-free at 866-767-3653, or via email at [email protected]. A class action lawsuit is already in progress, and if you aim to be a lead plaintiff, you must submit your motion to the Court by April 14, 2025. The lead plaintiff plays a crucial role in representing other class members within the case.

WHY ROSEN LAW: Investors are encouraged to choose legal counsel that possesses a rich background and record of success in significant roles. Many firms that issue notifications do not have the same level of experience, resources, or respect in the legal community. In fact, several of these firms do not actively litigate securities class actions; instead, they merely act as intermediaries that refer clients to more experienced law firms. Therefore, it is wise to carefully select your legal representation. Rosen Law Firm has a robust history of advocating for investors worldwide, focusing primarily on securities class actions and shareholder derivative lawsuits. The firm has achieved the largest securities class action settlement against a Chinese company at its time and was ranked No. 1 by ISS Securities Class Action Services for the volume of securities class action settlements in 2017. Since 2013, they have consistently ranked among the top firms and recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone. In 2020, Laurence Rosen, founding partner, was acknowledged by Law360 as a Titan of the Plaintiffs' Bar, and many attorneys at the firm are recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: The lawsuit asserts that throughout the Class Period, the defendants misled investors by providing key information regarding Intellia's ongoing Phase 1/2 study assessing NTLA-3001 for treating alpha-1 antitrypsin deficiency (AATD)-related lung disease. The defendants expressed confidence in Intellia's timeline for the study, specifically the expectation to dose the first patient by the second half of 2024. However, defendants failed to reveal that the demand for viral-based editing technologies was declining sharply as non-viral delivery methods gained traction due to their cost-effectiveness and efficiency, making NTLA-3001 a less viable option for Intellia. Once the truth surfaced in the market, the lawsuit claims that investors faced significant losses.

To learn more about joining the Intellia class action, please visit this link or reach out to Phillip Kim, Esq., toll-free at 866-767-3653, or via email at [email protected]. A class action lawsuit has already been initiated.

No Class Has Been Certified. Until certification, you are unrepresented unless you choose to retain counsel. You may appoint counsel of your preference or opt to remain an absent class member and take no action at this stage. Your potential recovery in the future does not rely on whether you serve as lead plaintiff.

Follow updates from Rosen Law Firm on LinkedIn: this link, on Twitter: this link, or on Facebook: this link.

Attorney Advertising. Past results do not guarantee similar outcomes.

-------------------------------

Contact Information:

Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, P.A.

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

www.rosenlegal.com

Intellia, Lawsuit, Investment